Aktis Oncology (AKTS) Stock Price, News & Analysis

Company Overview

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells.

The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

Aktis Oncology is based in Cambridge, Massachusetts, and focuses on research and clinical development of its radiopharmaceutical platform and product candidates.

Key Stats

• Today's Range: $15.76 to $16.42
• 50-Day Range: $14.59 to $27.05
• 52-Week Range: $13.96 to $34.19
• Volume: 56,739 shs
• Average Volume: 353,401 shs
• Market Capitalization: $866.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.63
• Consensus Rating: Moderate Buy

Aktis Oncology Stock Analysis - MarketRank™

Aktis Oncology scored higher than 33% of companies evaluated by MarketBeat, and ranked 689th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aktis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aktis Oncology has a consensus price target of $35.63, representing about 118.8% upside from its current price of $16.28.

Amount of Analyst Coverage

Aktis Oncology has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aktis Oncology are expected to decrease in the coming year, from ($1.84) to ($2.45) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.23% of the float of Aktis Oncology has been sold short.

Short Interest Ratio / Days to Cover

Aktis Oncology has a short interest ratio ("days to cover") of 16.02, which indicates bearish sentiment.

Change versus previous month

Short interest in Aktis Oncology has recently increased by 2.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aktis Oncology does not currently pay a dividend.

Dividend Growth

Aktis Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: -0.02

News Sentiment

Aktis Oncology has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Aktis Oncology this week, compared to 4 articles on an average week.

MarketBeat Follows

Only 1 people have added Aktis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aktis Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.30% of the stock of Aktis Oncology is held by insiders.

Percentage Held by Institutions

28.84% of the stock of Aktis Oncology is held by institutions.

Company Calendar

• Last Earnings: 11/12/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AKTS
• CIK: 2035832
• Web: www.aktisoncology.com
• Phone: (978) 237-4380
• Fax: N/A
• Employees: 79
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Aktis Oncology: $35.63
• High Price Target: $40.00
• Low Price Target: $31.00
• Potential Upside/Downside: +124.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.33
• Quick Ratio: 16.33

Sales & Book Value

• Annual Sales: $6.50 million
• Price / Sales: 131.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.89) per share
• Price / Book: -5.49

Miscellaneous

• Outstanding Shares: 53,750,000
• Free Float: 51,973,000
• Market Cap: $853.23 million
• Optionable: Optionable
• Beta: N/A